Abbott Laboratories $ABT Stock Holdings Lowered by Evolve Private Wealth LLC

Key Points

• Evolve Private Wealth LLC cut its Abbott Laboratories stake by 50.8% in the first quarter, leaving it with 20,807 shares valued at about $2.14 million.
• Abbott posted better-than-expected quarterly results, with EPS of $1.15 and revenue of $11.16 billion, while also guiding FY 2026 EPS to $5.38-$5.58.
• The company declared a quarterly dividend of $0.63 per share, implying an annualized yield of 2.9%; meanwhile, analysts still rate the stock a Moderate Buy with a consensus target of $118.30.

Evolve Private Wealth LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 50.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,807 shares of the healthcare product maker's stock after selling 21,473 shares during the period. Evolve Private Wealth LLC's holdings in Abbott Laboratories were worth $2,136,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $26,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ABT shares. Barclays dropped their price target on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research note on Monday, April 20th. Jefferies Financial Group dropped their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Oppenheimer reduced their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. Finally, Piper Sandler reiterated an "overweight" rating and set a $115.00 price objective on shares of Abbott Laboratories in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $118.30.

Abbott Laboratories Trading Down 0.7%

Abbott Laboratories stock opened at $87.78 on Tuesday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock has a market cap of $152.90 billion, a P/E ratio of 24.59, a P/E/G ratio of 1.52 and a beta of 0.63. The company's fifty day simple moving average is $89.78 and its 200-day simple moving average is $106.18.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period last year, the company earned $1.09 earnings per share. Abbott Laboratories's quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.9%. Abbott Laboratories's dividend payout ratio is currently 70.59%.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company's stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.